立方制药(003020.SZ)非奈利酮原料药上市申请获受理

Core Viewpoint - The company, Lifan Pharmaceutical, has received the acceptance notice for the listing application of Finerenone raw material from the National Medical Products Administration, indicating progress in its product development and potential market entry [1] Group 1: Product Information - Finerenone is a novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) [1] - The formulation is intended for adult patients with chronic kidney disease associated with type 2 diabetes, aiming to reduce the risk of sustained decline in eGFR and end-stage renal disease [1]